BioCentury | Feb 28, 2020
Finance

Passage prices upsized IPO despite market headwinds

The ability of Passage Bio to price its IPO above expectations late Thursday signaled that even with a global pandemic roiling markets, a new biotech listing can still pique investors’ interest. Gene therapy company Passage...
BioCentury | Feb 4, 2020
Finance

Co-founded by UPenn’s Wilson, Passage Bio outlines clinical goals in new IPO filing

Less than a year after emerging from stealth mode, gene therapy company Passage Bio revealed new details about its pipeline and clinical timelines through the filing of a prospectus for its planned IPO. Founded in...
BioCentury | Oct 24, 2019
Finance

Allievex, backed by Pappas and Novo, scoops up BioMarin ultra-rare disease assets

Pappas Ventures has founded Allievex to house a portfolio of rare disease candidates deprioritized by BioMarin, including a therapy for mucopolysaccharidosis IIIB that has reached clinical testing. Newly launched Allievex Corp. holds an exclusive, worldwide...
BC Extra | Sep 4, 2019
Financial News

Second megaround of ‘19 to help Passage broaden rare CNS disease pipeline

The gene therapy team and scientific foundation behind Passage Bio continue to attract investors, as the company said Wednesday it had raised $110 million in a series B round led by Access Biotechnology. The investment...
BioCentury | Mar 28, 2019
Finance

Polyneuron’s surgical strike

Polyneuron’s broad platform and method of directly targeting autoantibodies rather than B cells for autoimmune diseases prompted Sofinnova Partners and New Enterprise Associates to invest in the Basel-based company’s CHF22.5 million ($22.6 million) series A...
BC Extra | Mar 28, 2019
Financial News

Polyneuron raises $22.6M series A to bring neuropathy therapy into clinic

Backed by Sofinnova Partners and New Enterprise Associates, Polyneuron raised CHF22.5M ($22.6 million) in a series A round to bring its anti-MAG neuropathy therapy, PN-1007, into the clinic. Polyneuron Pharmaceuticals AG (Basel, Switzerland) is developing...
BC Innovations | Mar 21, 2019
Emerging Company Profile

A Passage to optimal CNS vectors

Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched...
BC Week In Review | Feb 15, 2019
Financial News

Passage Bio debuts with $115.5M for CNS gene therapies

Co-founded by gene therapy pioneer James Wilson, Passage Bio Inc. (Philadelphia, Pa.) launched with $115.5 million in series A funding Feb 14. Passage is developing five adeno-associated viral gene therapies to treat rare monogenic CNS...
BC Extra | Feb 14, 2019
Financial News

Passage Bio debuts with $115.5M for CNS gene therapies

Co-founded by gene therapy pioneer James Wilson, Passage Bio Inc. (Philadelphia, Pa.) launched with $115.5 million in series A funding Thursday. Passage is developing five adeno-associated viral gene therapies to treat rare monogenic CNS diseases...
BC Week In Review | Dec 21, 2018
Company News

Axovant gets rights to gene therapies from UMass medical school

The University of Massachusetts Medical School (Worcester, Mass.) granted Axovant exclusive, worldwide rights to develop and commercialize two gene therapies to treat GM1 and GM2 gangliosidoses. The school received $10 million up front and is...
Items per page:
1 - 10 of 26